Analysts’ Top Healthcare Picks: Y-Mabs Therapeutics Inc (YMAB), Sangamo Biosciences (SGMO)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Y-Mabs Therapeutics Inc (YMAB) and Sangamo Biosciences (SGMO) with bullish sentiments.

Y-Mabs Therapeutics Inc (YMAB)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Y-Mabs Therapeutics Inc today and set a price target of $40. The company’s shares closed last Monday at $25.77.

Selvaraju observed:

“We have assessed Y-mAbs using a discounted cash flow (DCF)-based methodology, which yields a total enterprise value of $1.46B. We utilize a 90% probability of approval for naxitamab in r/r neuroblastoma and for omburtamab in CNS/leptomenigeal metastases from neuroblastoma.”

According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -12.4% and a 24.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and Stealth Biotherapeutics Corp.

Y-Mabs Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $40, implying a 49.0% upside from current levels. In a report issued on August 15, Cowen & Co. also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Sangamo Biosciences (SGMO)

Sangamo Biosciences received a Buy rating and a $16 price target from H.C. Wainwright analyst Debjit Chattopadhyay today. The company’s shares closed last Monday at $11.02.

Chattopadhyay said:

“Our $16 price target is derived from a risk-adjusted, sum-of-the-parts analysis that drives our 13-year DCF model. Our DCF is based on: beta of 2.0, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.7%, and tax rate of 15% beginning in FY 2030. Our target is primarily leveraged to SB-525, which represents approximately 65% of our rNPV, i.e., $10.44 per share.”

According to TipRanks.com, Chattopadhyay is ranked 0 out of 5 stars with an average return of -6.7% and a 35.6% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Precision BioSciences Inc, and Voyager Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sangamo Biosciences with a $15 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts